Ganciclovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: denosine, ganciclovir sodium, gancyclovir, hydroxyacyclovir, natclovir
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ganciclovir is an ofp drug in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1989. Its mechanism of action is classified as DNA Polymerase Inhibitors. DrugCentral lists 7 molecular targets, including UL26, GRM1 and VCP. Recorded indications include CMV Retinitis in AIDS Patients, CMV Retinitis in Immunocompromised Patients, Cytomegaloviral retinitis and Herpes simplex dendritic keratitis.
- Approval status: ofp (first approved 1989 by the FDA).
- Drug class: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral.
- Mechanism of action: DNA Polymerase Inhibitors.
- Molecular targets: UL26, GRM1, VCP and GRM5 (7 listed in DrugCentral).
- Indications: CMV Retinitis in AIDS Patients, CMV Retinitis in Immunocompromised Patients, Cytomegaloviral retinitis, Herpes simplex dendritic keratitis and Myocardial Perfusion Imaging Adjunct and others.
- ATC code: J05AB06 (Nucleosides and nucleotides excl. reverse transcriptase inhibitors).
- Molecular formula: C9H13N5O4; molecular weight 255.23 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (11)
- CMV Retinitis in AIDS Patients
- CMV Retinitis in Immunocompromised Patients
- Cytomegaloviral retinitis
- Herpes simplex dendritic keratitis
- Myocardial Perfusion Imaging Adjunct
- Paroxysmal supraventricular tachycardia
- Prevention of CMV Disease After Cardiac Transplantation
- Prevention of CMV Disease After Kidney Transplantation
- Prevention of CMV Disease After Kidney-Pancreas Transplantation
- Prevention of CMV Disease After Organ Transplant
- Prevention of CMV Disease in Advanced HIV Patients
Off-label uses (4)
- CMV-Related Polyradiculopathy in AIDS Patients
- Cytomegalovirus infection
- Prevention of Cytomegalovirus Disease
- Supraventricular tachycardia
Contraindications (37)
- Acute cerebrovascular insufficiency
- Acute coronary syndrome
- Acute nephropathy
- Anemia
- Aortic valve stenosis
- Aplastic anemia
- Asthma
- Bilateral cataracts
- Breastfeeding (mother)
- Chronic obstructive lung disease
- Complete atrioventricular block
- Dehydration
- Disorder of autonomic nervous system
- Endophthalmitis
- Eye infection
- Granulocytopenic disorder
- Hypovolemia
- Kidney disease
- Left main coronary artery disease
- Left to right cardiovascular shunt
- Low blood pressure
- Mitral valve stenosis
- Neutropenic disorder
- Pericarditis
- Pulmonary emphysema
- Reduced visual acuity
- Respiratory alkalosis
- Respiratory insufficiency
- Retinal detachment
- Second degree atrioventricular block
- + 7 more
Mechanism & targets
| Mechanism of action (MoA) | DNA Polymerase Inhibitors |
|---|---|
| Established pharmacologic class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral |
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Capsid scaffolding protein | UL26 | unknown | EC50 6.07 |
| Metabotropic glutamate receptor 1 | GRM1 | unknown | Ki 6.05 |
| Transitional endoplasmic reticulum ATPase | VCP | unknown | IC50 5.89 |
| Metabotropic glutamate receptor 5 | GRM5 | unknown | Ki 5.41 |
| Purine nucleoside phosphorylase | punA | unknown | Kd 4.80 |
| DNA polymerase catalytic subunit | — | inhibitor | — |
| Thymidine kinase | TK | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1989-06-23 | FDA | — | ROCHE PALO | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AB06 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
S01AD09 | SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antivirals |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Cytomegalovirus infection | 2052.5 |
| Drug resistance | 1748.0 |
| Cytomegalovirus viraemia | 999.6 |
| Cytomegalovirus infection reactivation | 849.6 |
| Pathogen resistance | 838.8 |
| Off label use | 715.4 |
| Multiple organ dysfunction syndrome | 700.3 |
| Post transplant lymphoproliferative disorder | 667.3 |
| Pancytopenia | 636.3 |
| Graft versus host disease | 541.1 |
| Pneumonia cytomegaloviral | 529.1 |
| Cystitis haemorrhagic | 512.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ganciclovir is on its molecule page.
| Molecular formula | C9H13N5O4 |
|---|---|
| Molecular weight | 255.23 g/mol |
| CAS number | 82410-32-0 |
| InChIKey | IRSCQMHQWWYFCW-UHFFFAOYSA-N |
| PubChem CID | 135398740 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ganciclovir used for?
DrugCentral lists the following indications for Ganciclovir: CMV Retinitis in AIDS Patients, CMV Retinitis in Immunocompromised Patients, Cytomegaloviral retinitis, Herpes simplex dendritic keratitis, Myocardial Perfusion Imaging Adjunct, Paroxysmal supraventricular tachycardia, Prevention of CMV Disease After Cardiac Transplantation and Prevention of CMV Disease After Kidney Transplantation and others.
How does Ganciclovir work?
Ganciclovir is classified as DNA Polymerase Inhibitors; its molecular targets in DrugCentral include UL26, GRM1, VCP and GRM5.
When was Ganciclovir first approved?
Ganciclovir was first approved by the FDA in 1989.
What drug class does Ganciclovir belong to?
Ganciclovir is in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class.
What is the chemical formula of Ganciclovir?
Ganciclovir has the molecular formula C9H13N5O4 and a molecular weight of 255.23 g/mol.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1277 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200850 — compound record and bioactivity
- PubChem CID 135398740 — chemical identifiers
- DrugBank DB01004 — drug record
- FDA UNII P9G3CKZ4P5 — substance identity
- DailyMed: FDA labels for Ganciclovir — current prescribing information (label search)
- UniProt Q13255 (GRM1) — target protein
- UniProt P55072 (VCP) — target protein
- UniProt P41594 (GRM5) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.